SGPCRI@sgpcri

Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) fuels research, funds innovation, and drives global collaboration to fight pancreatic cancer.

sgpcri.global/
Joined February 2025
36 Photos and videos
SGPCRI retweeted
UC San Francisco@UCSF
22h
UCSF’s Kevan Shokat, PhD, just won the $1M Stephenson Global Prize for research in pancreatic cancer. He cracked KRAS, a cancer driver long considered “undruggable.” Drugs built on his work now treat lung and pancreatic cancer. ow.ly/xVlw50ZRSXh
Middle-aged man in a blue lab coat smiling while seated in a scientific laboratory setting.

ALT Middle-aged man in a blue lab coat smiling while seated in a scientific laboratory setting.

Hand wearing black glove holding five small glass vials with various colored liquids, including pink and orange hues.

ALT Hand wearing black glove holding five small glass vials with various colored liquids, including pink and orange hues.

9
49
405
37,738
Phenomenal talk by @kevansf at #AACRpan26 describing the journey to successfully targeting RAS. Well deserved honor from @sgpcri 💜
Anirban Maitra@Aiims1742
22h
Congratulations to the pioneer who started it all with his momentous discovery that mutant KRAS in cancer can be directly targeted and blocked: @kevansf @UCSFCancer on winning the @sgpcri Global Prize! KRAS inhibitors for the win! #AACRPan26
1
5
427
SGPCRI retweeted
AACR
@AACR
21h
#AACRFellows Kevan M. Shokat, PhD, FAACR was presented with the 2026 Stephenson Global Prize for research in pancreatic cancer and delivered his award lecture this afternoon during the AACR Conference on Pancreatic Cancer. #AACRpan26 @sgpcri
7
28
3,264
We’re proud to announce @kevansf as the recipient of the $1M Stephenson Global Prize for Pancreatic Cancer Research. His work helped turn “undruggable” KRAS into a target, opening possibilities for people facing pancreatic cancer. And his work is far from finished 🏆
1
9
11
971
The Stephenson Global Prize will be awarded TODAY 🏆 10:30 AM PT / 1:30 PM ET Watch the announcement live 👇 piped.video/watch?v=jYe1gx…
3
543
The next generation of pancreatic cancer researchers is already in the field. Whether they stay may depend on funding. Every researcher we lose could mean a breakthrough lost with them. Your gift could keep the right mind in this fight. Will you?
53
Can fighting pancreatic cancer mean looking beyond the tumor itself? Stephenson Scholar Liyuan (Liam) Ma, Ph.D., is exploring how boosting “bystander” T cells could break down tumor defenses and activate the body’s own cancer-fighting cells.
1
43
What if pancreatic cancer is hiding targets we haven’t been looking for? Stephenson Scholars William Freed-Pastor, M.D., Ph.D., and Jenn Abelin, Ph.D., are uncovering hidden “flags” that could help advance off-the-shelf vaccines and T-cell therapies.
1
44
To outsmart pancreatic cancer, we first need to understand how it adapts. Stephenson Scholar Tuomas Tammela, M.D., Ph.D., is studying aggressive cancer cell states that help tumors resist therapy, searching for vulnerabilities that could lead to more effective treatments.
1
48
Pancreatic cancer tumors may have found a way to shut T cells out. Dr. Koide’s team is working to open the door. Stephenson Scholar Shohei Koide, Ph.D., is developing antibodies targeting LCN2, a protein that helps keep cancer-fighting T cells from reaching tumors.
33
Most pancreatic precancers never become cancer. So what makes some turn dangerous? Stephenson Scholars Marina Pasca di Magliano, Ph.D., and Laura D. Wood, M.D., Ph.D., are studying K17-positive precancers to identify which are most likely to progress and how to stop them.
2
149
A new chapter in pancreatic cancer treatment starts today. The FDA has approved daraxonrasib, expanding treatment options for patients with metastatic pancreatic cancer. A win for patients, families and researchers. bit.ly/4qGPNJJ #PancreaticCancer

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced...

fda.gov
2
95
What happens when a promising pancreatic cancer treatment stops working? Stephenson Scholars Erik S. Knudsen, Ph.D., and Agnieszka K. Witkiewicz, M.D., are studying resistance to RAS-targeted therapies to help treatments work better, for longer.
37
Can pancreatic cancer’s own biology become its weakness? Stephenson Scholar Cristian Prieto García, DVM, Ph.D., is investigating a new way to target cancer cells from within, with the potential to create new treatment options. #PancreaticCancer #CancerResearch
2
3
130
What if a blood test could determine if pancreatic cysts are dangerous before they become cancer? Stephenson Scholar Ajay Goel, Ph.D., is working to make that possible, advancing a noninvasive approach to earlier pancreatic cancer detection. #PancreaticCancer #CancerResearch
1
2
80
The hardest disease demands relentless minds. That's why we're proud to support the scientists taking on one of medicine's greatest challenges. sgpcri.org

Home - Stephenson Global Pancreatic Cancer Research Institute

Learn about Stephenson Global Pancreatic Cancer Research Institute's mission to end pancreatic cancer by funding groundbreaking and innovative research.

sgpcri.global
1
51
Extraordinary discoveries deserve extraordinary recognition. Last year, we honored Dr. Frank McCormick as the inaugural recipient of the Stephenson Global Prize. Stay tuned as we announce this year's Prize recipient at the AACR Special Conference on Pancreatic Cancer.
1
56
The FDA has accepted the New Drug Application for daraxonrasib, bringing a potential new treatment for metastatic pancreatic cancer one step closer to patients. Read more: bit.ly/3RxpfOa

FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer | CancerNetwork

The FDA has accepted the new drug application for daraxonrasib in metastatic pancreatic ductal adenocarcinoma based on results from the phase 3 RASolute 302 study.

cancernetwork.com
1
1
163
One cohort. Eleven researchers. A shared commitment to changing the future of pancreatic cancer. Meet the 2026 Stephenson Scholars. The next chapter of their research begins this September. bit.ly/4bN1mZV
1
2
2
6,212
Our purpose is to end pancreatic cancer. Period. History is full of things that seemed impossible, until they weren't. The challenge is enormous. So is our commitment to changing it. sgpcri.org

Home - Stephenson Global Pancreatic Cancer Research Institute

Learn about Stephenson Global Pancreatic Cancer Research Institute's mission to end pancreatic cancer by funding groundbreaking and innovative research.

sgpcri.global
1
87
Load more